NCT02423525: Safety Study of Afatinib for Brain Cancer

NCT02423525
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: Breast cancer patients are only eligible for dose escalation phase
Exclusions: 
https://ClinicalTrials.gov/show/NCT02423525

Comments are closed.

Up ↑